Benzinga | Nov 2, 2021 05:08PM EDT

Corvus Pharmaceuticals To Present Updated Mupadolimab Data At 2021 Society For Immunotherapy Of Cancer Annual Meeting

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it will present data from its Phase 1/1b trial of mupadolimab at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place on November 10-14, 2021.

The updated data from the mupadolimab study will be presented in a poster at SITC. Details of the poster presentation are as follows:

Activating CD73 on B cells as a target for immunotherapy of COVID-19Title: and viral associated cancers: Clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC)Presenter: Jason J. Luke, M.D, University of Pittsburgh School of MedicineCategory: Immune-stimulants and immune modulatorsPoster #: 701Date & Friday, November 12, 2021, 7:00 a.m. ? 8:30 p.m. ETTime:Location: Walter E. Washington Convention Center, Hall E, or https:// www.sitcancer.org/2021/home